Table 2 Details of treatment post ASCT.
Variable | Cohort (n = 292) |
|---|---|
Treatment post ASCT, n (%) | |
Alkylator + PI ± dex, or PI ± dex | 118 (40) |
CyBorD | 64 (54) |
Vd | 51 (43) |
Id | 2 (2) |
VMP | 1 (1) |
Alkylator + 2nd-gen IMiD ± dex, or 2nd-gen IMiD ± dex | 77 (26) |
Rd | 59 (77) |
Pd | 10 (13) |
CRd | 8 (10) |
Alkylator + steroid, or steroids monotherapy | 55 (19) |
Melphalan + steroids | 39 (71) |
Cyclophosphamide + steroids | 2 (4) |
dex | 14 (25) |
2nd-gen IMiD + PI ± dex | 17 (6) |
VRd | 10 (59) |
IRd | 5 (29) |
KPd | 1 (6) |
KRd | 1 (6) |
Alkylator + thalidomide ± dex | 14 (5) |
Td | 13 (93) |
CTd | 1 (7) |
Daratumumab-based | 11 (4) |
Dara ± dex | 6 (55) |
DPd | 3 (27) |
DRd | 1 (9) |
DVd | 1 (9) |
